Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Anesthesiology and Critical Care Medicine Faculty
Publications

Anesthesiology and Critical Care Medicine

2-15-2012

TRPV1 antagonists may exacerbate sepsis in aged
mice: Should we be nervous?
Zenaide M.N. Quezado
George Washington University

Arpad Szallasi
Monmouth Medical Center, Long Branch, NJ

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_anesth_facpubs
Part of the Anesthesia and Analgesia Commons
Recommended Citation
Quezado, Z.M., Szallasi, A. (2012). TRPV1 antagonists may exacerbate sepsis in aged mice: Should we be nervous?. Cell Cycle, 11(4),
647-648.

This Response or Comment is brought to you for free and open access by the Anesthesiology and Critical Care Medicine at Health Sciences Research
Commons. It has been accepted for inclusion in Anesthesiology and Critical Care Medicine Faculty Publications by an authorized administrator of
Health Sciences Research Commons. For more information, please contact hsrc@gwu.edu.

cell cycle news & views

cell cycle news & views

Cell Cycle 11:4, 645-651; February 15, 2012; © 2012 Landes Bioscience

Cell Cycle News & Views
Micronucleophagy: A new mechanism to protect against
chromosomal instability?
Comment on: Rello-Varona S, et al. Cell Cycle 2012; 11:170–6; PMID:22185757;
http://dx.doi.org/10.4161/cc.11.1.18564
Patricia Boya1 and Patrice Codogno2; 1CIB; Consejo Superior de Investigaciones Cientificas (CSIC); Madrid, Spain; 2INSERM U984; University Paris-Sud 11;
Châtenay-Malabry, France; *Email: pboya@cib.csic.es and patrice.codogno@u-psud.fr; http://dx.doi.org/10.4161/cc.11.4.19278

Micronuclei are small membrane-enclosed
cytoplasmic bodies containing whole or fragmented chromosomes, which are formed
during anaphase in aberrant mitosis and in
response to genotoxic stress. In the latter
scenario, the formation of micronuclei can be
used to assess the toxicity of various chemicals
and drugs. A report by Rello-Varona et al. in
a previous issue describes the elimination of
micronuclei by autophagy.1
Macroautophagy (hereafter referred to
as autophagy) is a highly regulated cellular mechanism for degradation and recycling
of cytoplasmic contents. This process begins
with the formation of an autophagosome,
a double membrane structure that engulfs
parts of the cytosol and whole organelles,
finally fusing with a lysosome to allow the
degradation of the enclosed material. The
final products, including amino acids, lipids
and nucleotides, are released into the cytosol via permeases present at the lysosomal
membrane and can then be used for anabolic reactions to maintain cellular functions.
Autophagy is conserved from yeast to human
and is regulated by the Atg family of proteins.2
Autophagy is a general response to cellular
stress, which mediates the clearance of dangerous cell components, such as damaged
mitochondria, and intracellular pathogens,
such as viral particles and bacteria.3
The study by Rello-Varona and colleagues
demonstrates that micronuclei generated
after cell cycle perturbations are surrounded
by LC3- and p62-positive staining (Fig. 1). This
phenomenon appears to be dependent on
the autophagy regulators Atg7 and Atg5, as
it is not observed in cells treated with siRNAs
for Atg5 and Atg7. Importantly, these micronuclei contain a reduced quantity of DNA, as
determined by DNA binding dyes and fluorescent histone tagging, and exhibit a discontinuous membrane, suggesting that both the
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Figure 1. Schematic representation of markers during micronucleophagy.
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nuclear membrane and DNA are degraded by
autophagy. As expected, these structures were
also positive for the lysosomal marker Lamp2.
Interestingly, only micronuclei presenting
symptoms of DNA damage were targeted, as
indicated by labeling with phospho-γH2AX, a
marker of DNA damage.1
Selective autophagy of organelles (e.g.,
mitochondria) and intracellular pathogens
requires the recognition of LC3-interacting
regions in target proteins at the surface
of organelles and intracellular bacteria.4
Interestingly, Rello et al. report that micronuclei were also positive for p62, an LC3interacting protein,5 whereas no p62 staining
was detected in LC3-negative micronuclei. It
remains to be determined whether p62 represents the bona fide receptor for this new
form of selective autophagy or micronucleophagy. Moreover, further studies are required
to determine how DNA damage promotes
LC3 recognition, leading to the elimination of
potentially harmful cellular structures.
Degradation of nuclear-derived material
and even entire nuclei by autophagy has been
previously described in non-vertebrates. In
fact, several studies have shown that part of

Cell Cycle

the nucleus can be removed by piecemeal
microautophagy of the nucleus,6 so called
because no vesicular membrane-bound intermediates are created. Furthermore, in syncytial
fungi the entire nucleus can be degraded by
autophagy. It thus seems plausible that the
size of the material undergoing degradation
does not limit the nuclear degradation process. Indeed, giant LC3-positive structures are
observed when S. aureus invades mammalian
cells.7 Selectivity, rather than the target size,
thus appears to be the most important aspect
of this process.
Autophagy plays an important role in limiting DNA damage and genomic instability; 8
the relevance of the findings of Rello-Varona
to these processes remains to be determined.
Further investigation of these phenomena,
both in tumors and in autophagy-deficient
cells in vivo, is thus required to determine
whether micronucleophagy may be used to
limit the consequences of chromosomal instability. This new form of selective autophagy
adds yet more intracellular structures and
organelles to the growing list of cellular components that are specifically targeted for lysosomal degradation.
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Animals have evolved a strategic set of
responses to control and react against infection by pathogens and tissue injury, which,
together, comprise the process of inflammation.1 Inflammation is initially a beneficial
reaction for the host; however, if prolonged,
becoming chronic inflammation, it can be
detrimental and lead to the development or
aggravation of several pathologies, including
cancer.1,2 These harmful effects of the inflammatory response have attracted considerable
attention in therapeutic drug generation.
As a result, much effort has been directed
at blocking the activity of one of the central
players in inflammation: NFκB.1-3 NFκB is an
evolutionarily-conserved family of transcription factors that plays a crucial role in innate
immunity by driving the expression of a variety of inflammatory mediators, such as cytokines and chemokines, and genes involved in
pro-survival and anti-apoptotic signaling.3
A prolonged or persistent activation of
NFκB can be harmful for an organism, yet it
mediates multiple functions that are vital for
health and host defense.1-3 As a corollary, a
complete block of NFκB activity would not
be always advantageous. An attempt to solve
this issue has been to identify drugs which
selectively act only on specific downstream
NFκB targets.2
Most NFκB targets are activated in a celltype and stimulus-specific fashion.3 NFκBs act
in the form of homo- and heterodimers and,
in some cases, target genes are activated only
by particular dimer combinations, whereas
others are activated redundantly by multiple

different dimers.3,4 Each NFκB dimer binds
to a 9–10bp DNA motif (the “kb site”), which
represents the first level of target specificity.3,4
However, although in vitro most dimers bind
to all kb sites with high affinity, it is increasingly evident that in vivo, the various dimers
display different abilities to bind to particular
kb sites: the rules which constrain this are
under active investigation but are still not
completely clear. Subsequent transcriptional
activation of target genes by NFκB is also
the result of multiple levels of integrated
regulation, including nucleosome positioning
at the target site, the effects of permissive/
repressive histone modifications and posttranslational modifications to NFκB itself.3-6
In particular, it has been shown that phosphorylation of the NFκB subunit p65 at different residues has a series of transcriptional
effects.4,5,7 In keeping with current efforts to
characterize drugs capable of targeting only
certain aspects of NFκB activity, Mora et al.8
showed, in a previous issue of Cell Cycle, that
Bindarit, a proven anti-inflammatory drug, targets a specific pool of p65-containing dimers
in activated macrophages. Bindarit has been
in use for some years and is known to interfere with monocyte recruitment during early
inflammatory responses by regulating production of the chemokine MCP1.9 They have
now shown that Bindarit causes a partial
block in IκBα phosphorylation, p65 nuclear
entry and its phosphorylation at S536. This
results in a decrease in the transcriptional
activation of MCP18 together with a handful
of other inflammatory genes.

Importantly, many other NFκB target
genes are unaffected by treatment with
Bindarit. This highlights the importance of
targeting specific facets of NFκB and also
reveals that the decrease (but not elimination)
of nuclear p65 and, in particular, of the S536phosphorylated form, differentially affects its
binding to particular kb sites at target genes.
Thus, Bindarit seems to regulate inflammation
by selectively modulating the activation of a
subset of chemokines and, in so doing, reducing amplification of inflammation without
eliminating it.8
While this work provides a first, fascinating
glimpse of how Bindarit controls the activation of MCP1 (along with several other target genes), it raises some new, unanswered
questions. Additional studies will be needed
in order to identify the effector molecule(s)
responsible for the reduced activation of
p65-containing dimers (one possibility is that
Bindarit may be acting as an inhibitor of IKKβ,
which is known to phosphorylate both IkBα
and p655) and the extent to which Bindarit
affects the activity of other NFκB dimers.
In the future, it is likely that increasing
attention will be focused on developing
drugs which, like Bindarit, control specific
subsets of NFκB targets without disrupting
the entire inflammatory system. Other areas
which may be interrogated as possible drug
targets include the various other post-translational modifications of the NFκB subunits
as well as aspects of chromatin structure thatmay discriminate specific subsets of target
genes.1,2,6,8
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Desensitization of nociceptive neurons to capsaicin has a clear analgesic potential. Indeed, a
high concentration capsaicin patch is already
in clinical use to relieve neuropathic pain. The
cloning of the capsaicin receptor TRPV1 has
spurred considerable efforts in the pharmaceutical industry to find potent, small-molecule TRPV1 antagonists.1 However, adverse
effects have so far prevented any TRPV1 antagonists from advancing beyond phase II trials.
In particular, concerns have surfaced around
the effects of antagonizing TRPV1 on thermoregulation (hyperthermia) and on the ability to
detect noxious heat (risk for scalding injury).1
In a previous issue, Romanovsky and coworkers raised the possibility that TRPV1 blockade
might also affect the response to sepsis, especially in older hosts.2
This is concerning, because both systemic
inflammatory response syndrome (SIRS),
which can occur following tissue damage, and
sepsis, which occurs with microbial infection,
are major public health problems and cause
thousands of deaths every year.3,4 In addition,
despite extensive research into the inflammatory cascade triggered during SIRS and sepsis,
the field has witnessed many failed clinical
trials with drugs that alter the inflammatory
response.3 That some anti-inflammatory drugs
lacked beneficial effects while others were
harmful attests to the complexity and to the
potential hazard of perturbing the inflammatory response.
Researchers have shown that the inflammatory response is modulated by a number of humoral and neural processes.
Among the neural processes, the cholinergic

anti-inflammatory pathway is long recognized.5 More recently, TRPV1-expressing
sensory neurons have emerged as potential players in modulating the inflammatory
response during SIRS and sepsis. But how
can TRPV1-expressing neurons play a role in
inflammation? These neurons are known to
release neuropeptides (e.g., substance P and
calcitonin gene-related peptide) that initiate
the cascade of neurogenic inflammation.1
Indeed, TRPV1 blockade decreases neurogenic
inflammation.6
Recent studies demonstrate that during
LPS-induced SIRS in mice, TRPV1 deficiency
is associated with increased inflammatory
mediators and exacerbated organ damage.7
Moreover, pharmacological TRPV1 blockade
decreases survival.8 However, the effect of
TRPV1 actually varies depending on the insult
(sepsis or LPS) and the mode of receptor blockade (desensitization, antagonism or gene disruption). In mice, both genetic deletion of
TRPV1 and its desensitization to the ultrapotent agonist resiniferatoxin worsen survival
and decrease bacterial clearance during polymicrobial sepsis but were without significant
effect when LPS (without infection) triggered
the inflammatory response.8
Studies with the relatively non-selective
TRPV1 antagonist, capsazepine, yielded conflicting results. In mice with LPS-induced
SIRS, capsazepine worsened survival.8 By contrast, when administered before the onset
of infection and sepsis, capsazepine actually
improved survival.9 Clearly, the role of TRPV1expressing sensory neurons in SIRS and sepsis
is incompletely understood, and the net effect

of TRPV1 disruption seems to vary depending
on the insult and the mode of disruption.
An underrecognized factor in TRPV1
actions is aging. For example, compared with
their wild-type littermates, Trpv1-knockout
mice are leaner when they are young but are
more obese when they are getting old.1
Using a potent and selective TRPV1 antagonist, AMG517, Romanovsky suggests that
aging may also alter the role of TRPV1 in LPSinduced SIRS.2 While some might question
the statistical power of some experiments,
they confirm previous findings with capsazepine in young animals that TRPV1 antagonism worsens survival after LPS challenge.
Surprisingly, this effect is reversed in older
mice where AMG517 improves survival. These
findings suggest that during LPS-induced SIRS,
the role of TRPV1 might reverse with aging
from anti-inflammatory to pro-inflammatory.
Conversely, in the setting of infection, older
TRPV1-deficient animals die earlier than controls, similar to findings previously reported in
younger septic mice.8
In conclusion, aging seems to reverse the
role of TRPV1 from anti-inflammatory to proinflammatory during SIRS but not sepsis. This
is supported by the decreased serum levels
of tumor necrosis factor, a known pro-inflammatory mediator, in LPS-challenged Trpv1knockout older mice.2 While it is tempting to
categorize TRPV1 as anti-inflammatory vs. proinflammatory, one might argue that the inflammatory response in SIRS and sepsis is complex,
and the presented data are far from being
conclusive. Despite these issues, this is an
important contribution to our understanding
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of the role of TRPV1 in inflammatory response.
Indeed, since TRPV1 blockade has been used
clinically,1 there is a real need to investigate
the mechanisms involved more deeply. Should
we be nervous? At a minimum, we should be
vigilant.
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Despite the growing number of functions
assigned, ranging from pigmentation to fertility, the main role of the tumor suppressor protein p53 remains to preserve genome integrity
by controlling two key biological outcomes
of genome perturbation: the induction of cell
cycle arrest, allowing DNA repair or, when
the damage is irreparable, the induction of
programmed cell death.1 The choice between
cell cycle arrest and apoptosis is influenced by
different p53-dependent transcriptional programs that either involve cyclin-dependent
kinase inhibitors (such as p21/WAF1) or apoptotic genes, such as p53AIP1, NOXA and Bax.2
How the decision is made at the molecular level is still the focus of intense research
efforts, but it is clear that p53 post-translational modifications are key determinants of
this decision: p53 phosphorylation on Ser-15
and Ser-20 residues is associated with cell
cycle arrest, while Ser-46 phosphorylation is
linked to cell death.3 Protein acetylation at
defined residues was also associated to the
activation of apoptotic genes by p53. More
recently, p53 ubiquitination, was found to
affect, under certain conditions, the activity
of p53 rather than stability. Ubiquitinated p53
was found in complexes bound to cell cycle
arrest but not apoptosis genes, suggesting
that p53 ubiquitination contributes to the
selection of its transcriptional targets.4 p53
ubiquitination is influenced by a plethora of
ubiquitin ligases, most of them characterized
for their ability to flag p53 for proteasomemediated degradation.5
Among these, recent studies have indicated
that some members of the tripartite motif

(TRIM) proteins (one of the subfamilies of the
RING type E3 ubiquitin ligases), which function
as important regulators for carcinogenesis, are
downregulated in tumors and act as important
p53 regulators.6 The RING domain of TRIM24
functions as an E3-ubiquitin ligase that targets
p53 for degradation, and its depletion induces
p53-dependent apoptosis.7 The promyelocytic
leukemia protein PML/TRIM19 is a p53 target
that facilitates p53-Thr18 phosphorylation in
response to DNA damage by recruiting p53
into PML nuclear bodies, thereby leading to
p53 activation by protecting it from MDM2
inhibition. More recently, the ataxia telangiectasia group D-complementing ATDC/TRIM29
protein has been shown to bind and antagonize p53-mediated functions.6
In a very interesting article appeared in
a previous issue of Cell Cycle, Caratozzolo
and colleagues8 identified in the E3 ubiquitin ligase TRIM8 as a key regulator of p53 in
the cell cycle arrest vs. apoptosis decision.
They showed that p53 directly activates TRIM8
transcription after DNA damage through a
p53-responsive element in the first intron of
TRIM8 gene. Once upregulated by p53, TRIM8
directly interacts with p53, inducing its stabilization by inhibiting MDM2 binding and, most
interestingly, activating the cell cycle arrest
transcriptional program but not apoptosis. This
is accompanied by an increase of Ser-15 and
Ser-20 phosphorylated p53 level but not of
Ser-46, and, indeed, selective TRIM8 depletion facilitates DNA damage-induced apoptosis. Exogenous TRIM8 expression induced cell
cycle arrest only in cell lines harboring wildtype p53 and had no effect in p53-null cells,

indicating that TRIM8-induced cell cycle arrest
is p53-dependent.
These findings highlight the importance
of a novel feedback loop regulating the
p53-dependent transcriptional program activated by DNA damage. Naturally, the findings
of Caratozzolo et al. also generate questions.
How does TRIM8 affect p53 ubiquitination?
How are TRIM8 binding and p53 phosphorylation interconnected? Which comes first? Does
TRIM8 also affect p53 acetylation? Are the
other p53 family members involved in this
feedback loop?
Future studies will certainly help address
some of these questions and enhance our
understanding of p53-related network, the
ultimate beneficiaries being cancer-afflicted
patients and their families.
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Sgo1 as a “guardian spirit” for preventing colon tumorigenesis
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High-fidelity chromosome segregation during both mitosis and meiosis is essential for
the propagation and inheritance of stable
genomes. Defects in these fundamental processes promote aberrant chromosome segregation, which, in the absence of cell death,
produces aneuploid progeny. In somatic cells,
aneuploidy is a putative cancer-promoting
event. In germ cells, aneuploidy can reduce
reproductive fertility and promote the accumulation of trisomies, such as those associated
with Down, Patau or Edward syndromes. In
order for maintenance of genomic integrity,
cells have an elaborate network of proteins
that function during mitosis and meiosis to
ensure accurate chromosome segregation.
One such proposed mitotic regulator is shugoshin. Whereas budding yeast and Drosophila
contain a single shugoshin gene, fission yeast
and mammals have two paralogs (Sgo1 and
Sgo2). The exact role of the shugoshin family of proteins during mitosis and meiosis
has been somewhat elusive. Several functions have been proposed for Sgo1, including protecting centromeric cohesion through
associating with PP2A phosphatase,1 ensuring
attachment error correction through chromosome passenger complex positioning,2 maintaining centriole cohesion3 and mediating
kinetochore microtubule attachment by interacting directly with spindle microtubules.4 Like
Sgo1, Sgo2 has also been similarly implicated
in centromeric cohesion and attachment error
correction, although under different cellular
circumstances than Sgo1. On the other hand,
Sgo2, but not Sgo1, is thought to function
during mitosis through binding spindle microtubules through its association with astrin5 and
through binding Mad2.6 Until now, the physiological consequences of deregulated Sgo1
had been unknown.

In a previous issue of Cell Cycle, Yamada and
colleagues set out to assess the cellular and
physiological consequences of reduced Sgo1
expression,7 since mouse Sgo1 encodes an
essential gene. Importantly, which functions of
Sgo1 are required for cell viability and whether
this occurs at centromeres or centrosomes
remains unknown. One hint that centromeric,
mitotic Sgo1 may not be required for viability,
however, comes from the observation that
interphase Sgo1 is sufficient for the establishment of centromeric cohesion.8 This raises the
question of what the function of mitotic Sgo1
is, in addition to whether and how it contributes to chromosome segregation. Consistent
with the reported roles of Sgo1, mouse embryonic fibroblasts haploinsufficient for Sgo1 harbored both amplified centrosomes as well as
chromosomes that were improperly attached
to spindle microtubules. Whether the attachment defect was due to aberrant geometries
from centrosome amplification,9 reduced correction of defective kinetochore microtubule
interactions or precocious separation of sister
chromatids is not known.
Because diminished Sgo1 expression had
been previously linked to human colon neoplastic lesions, Yamada and colleagues challenged Sgo1 heterozygous mice with AOM,
a carcinogen that generates DNA damage
to initiate colon carcinogenesis. Importantly,
mice heterozygous for Sgo1 harbored 5-fold
more colon adenomas than wild-type mice at
12 weeks after completion of AOM treatment.
Rather intriguingly, mice haploinsufficient for
Sgo1 were actually more prone to cell death in
the colonic mucosa compared with wild-type
mice, at least in the initial phase of the experiment. This is a first demonstration of enhanced
cell death following carcinogen challenge in
a chromosomally unstable murine model.

However, it remains an open question how
enhanced cell death, although only immediately following carcinogen challenge, might
alter the delicate balance regulating cell proliferation vs. cell death to influence tumor
progression. This relationship could have significant implications in tumor etiology, progression and aggressiveness.
In summary, this study provides a causal
link between diminished Sgo1 expression
and induction of carcinogen-induced colon
tumorigenesis. Additionally, these experiments raise a number of intriguing questions
concerning the molecular mechanism for how
Sgo1 contributes to high-fidelity chromosome
segregation. The study of Sgo1 in mammals
continues the line of investigation that began
with the study of a single shugoshin gene
in budding yeast and will likely lead to an
increased understanding of the multiple layers
of regulation necessary for proper chromosome segregation.
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Centrosome amplification and aneuploidy
are commonly observed features of cancer
cells. Whether these defects are a cause or
a consequence of cancer development has
been a subject of intense recent research. The
generation of multiple knockout mouse models for genes involved in the spindle checkpoint, kinetochore-microtubule attachment or
mitotic exit has provided strong evidence linking mitotic defects to chromosome instability
and tumorigenesis.1 Loss-of-function mutations of these mitotic regulators are, however,
rarely found in tumor samples from human
patients, suggesting that the chromosome
instability observed in most tumors is due to
defects in other processes. Recently, genomic
studies using patient samples have implicated
genes involved in chromosome cohesion as
a likely source of chromosome instability in
tumors.2,3
Chromosome cohesion is established
during DNA replication in S phase and is
required to keep the two sister chromatids
together until anaphase, when the sister chromatids are segregated into the two daughter cells. Central to the cohesion process are

the cohesin complex (which is composed of
Smc1, Smc3, Scc1, and SA1/2) and multiple
cohesin regulators that load (Scc2-Scc4), stabilize (Esco1/2 and sororin), protect (Sgo1)
or remove (Wapl and separase) cohesin from
chromosomes during the proper stages of the
cell cycle. Most cohesin on chromosome arms
is removed during early mitosis by mitotic
kinases and Wapl. A small of pool of cohesin
at the centromeres is protected by the complex between shugoshin (Sgo1) and PP2A.4,5
This centromeric pool of cohesin is cleaved
by separase following the biorientation of
all sister chromatids and the silencing of the
spindle checkpoint. Inactivation of Sgo1 leads
to premature sister-chromatid separation in
cultured human cells.4,5
Mutations of multiple components of the
cohesion pathway, including Smc1, Smc3 and
SA2 were found in human cancers.2,3 However,
whether mutations of cohesin and its regulators directly contributed to chromosome
instability and tumorigenesis remained to be
tested. The work by Yamada and coworkers in
a previous issue of Cell Cycle shed light on this
matter.6 By generating Sgo- knockout mice, the

authors were able to test whether reduction in
Sgo1 levels resulted in chromosome instability
and tumor formation. As expected, due to the
key role of Sgo1 in cohesion protection, homozygous Sgo1-knockout mice were embryonic
lethal. However, heterozygous Sgo1+/− mice
were viable, and cells from these mice showed
an increase in chromosome segregation
defects, including chromosome misalignment,
lagging chromosomes and the formation of
anaphase bridges. Ultimately, these defects
led to an increase in the number of aneuploid
and polyploid cells, indicating that Sgo1 mutations were sufficient to cause chromosome
instability. Most importantly, Sgo1+/− mice
showed a 5-fold increase in the formation of
colon tumors when challenged with a carcinogen, establishing a direct link between Sgo1
haploinsufficiency and increased tumorigenic
potential.
Another phenotype observed by Yamada
and colleagues in Sgo1+/− cells was centrosome amplification. Prior studies had implicated a short splice variant of Sgo1 (sSgo1),
cohesin, and separase in regulating the centrosome cycle.7-9 Thus, different splicing variants
of Sgo1 appear to have specific roles at the
centromeres and the centrosomes. Selective
complementation of Sgo1+/− cells that are deficient for both splicing isoforms will determine
the specific cellular functions of each isoform. More importantly, complementation of
Sgo1+/− mice with different Sgo1 isoforms will
reveal the individual contributions of cohesion
defects and centrosome amplification to cancer development.
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Figure 1. The chromosome and spindle abnormalities observed in Sgo1- or cohesin-deficient cells
and their potential roles in generating chromosome instability.
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